Telomere shortening at chromosomal ends due to the constraints of the DNA replication process acts as a tumor suppressor by restricting the replicative potential in primary cells. Cancers evade that limitation primarily through the reactivation of telomerase via different mechanisms. Mutations within the promoter of the telomerase reverse transcriptase (TERT) gene represent a definite mechanism for the ribonucleic enzyme regeneration predominantly in cancers that arise from tissues with low rates of self-renewal. The promoter mutations cause a moderate increase in TERT transcription and consequent telomerase upregulation to the levels sufficient to delay replicative senescence but not prevent bulk telomere shortening and genomic instability. Since the discovery, a staggering number of studies have resolved the discrete aspects, effects and clinical relevance of the TERT promoter mutations. The promoter mutations link transcription of TERT with oncogenic pathways, associate with markers of poor outcome and define patients with reduced survivals in several cancers. In this review, we discuss the occurrence and impact of the promoter mutations and highlight the mechanism of TERT activation. We further deliberate on the foundational question of the abundance of the TERT promoter mutations and a general dearth of functional mutations within noncoding sequences, as evident from pan-cancer analysis of the whole-genomes. We posit that the favorable genomic constellation within the TERT promoter may be less than a common occurrence in other noncoding functional elements. Besides, the evolutionary constraints limit the functional fraction within the human genome, hence the lack of abundant mutations outside the coding sequences.

Department of Molecular Biology of Cancer Institute of Experimental Medicine of the Czech Academy of Sciences Prague Czech Republic

Division of Functional Genome Analysis German Cancer Research Center Heidelberg Germany

Zobrazit více v PubMed

Roake CM, Artandi SE. Regulation of human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol. 2020;21:384-397.

Heidenreich B, Kumar R. TERT promoter mutations in telomere biology. Mutat Res. 2017;771:15-31.

Maciejowski J, de Lange T. Telomeres in cancer: tumour suppression and genome instability. Nat Rev Mol Cell Biol. 2017;18:175-186.

Nandakumar J, Cech TR. Finding the end: recruitment of telomerase to telomeres. Nat Rev Mol Cell Biol. 2013;14:69-82.

O'Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol. 2010;11:171-181.

Sfeir A, Kosiyatrakul ST, Hockemeyer D, et al. Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell. 2009;138:90-103.

Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. Science. 2015;350:1193-1198.

Ruis P, Boulton SJ. The end protection problem-an unexpected twist in the tail. Genes Dev. 2021;35:1-21.

Ruis P, Van Ly D, Borel V, et al. TRF2-independent chromosome end protection during pluripotency. Nature. 2021;589:103-109.

Lim CJ, Cech TR. Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization. Nat Rev Mol Cell Biol. 2021;22:283-298.

Sfeir A, de Lange T. Removal of shelterin reveals the telomere end-protection problem. Science. 2012;336:593-597.

de Lange T. How shelterin solves the telomere end-protection problem. Cold Spring Harb Symp Quant Biol. 2010;75:167-177.

Martínez P, Blasco MA. Replicating through telomeres: a means to an end. Trends Biochem Sci. 2015;40:504-515.

Ohki R, Tsurimoto T, Ishikawa F. In vitro reconstitution of the end replication problem. Mol Cell Biol. 2001;21:5753-5766.

de Lange T. Shelterin-mediated telomere protection. Annu Rev Genet. 2018;52:223-247.

Huffman KE, Levene SD, Tesmer VM, Shay JW, Wright WE. Telomere shortening is proportional to the size of the G-rich telomeric 3′-overhang. J Biol Chem. 2000;275:19719-19722.

Timashev LA, De Lange T. Characterization of t-loop formation by TRF2. Nucleus. 2020;11:164-177.

Sarek G, Kotsantis P, Ruis P, et al. CDK phosphorylation of TRF2 controls t-loop dynamics during the cell cycle. Nature. 2019;575:523-527.

Wu P, van Overbeek M, Rooney S, de Lange T. Apollo contributes to G overhang maintenance and protects leading-end telomeres. Mol Cell. 2010;39:606-617.

Hayflick L. The illusion of cell immortality. Br J Cancer. 2000;83:841-846.

Srinivas N, Rachakonda S, Kumar R. Telomeres and telomere length: a general overview. Cancer. 2020;12:558.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.

Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38:6172-6183.

Chakravarti D, LaBella KA, DePinho RA. Telomeres: history, health, and hallmarks of aging. Cell. 2021;184:306-322.

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194-1217.

Opresko PL, Shay JW. Telomere-associated aging disorders. Ageing Res Rev. 2017;33:52-66.

Shay JW. Role of telomeres and telomerase in aging and Cancer. Cancer Discov. 2016;6:584-593.

Grill S, Nandakumar J. Molecular mechanisms of telomere biology disorders. J Biol Chem. 2020;296:100064.

Sarek G, Marzec P, Margalef P, Boulton SJ. Molecular basis of telomere dysfunction in human genetic diseases. Nat Struct Mol Biol. 2015;22:867-874.

Xi L, Cech TR. Inventory of telomerase components in human cells reveals multiple subpopulations of hTR and hTERT. Nucleic Acids Res. 2014;42:8565-8577.

Jiang J, Wang Y, Sušac L, et al. Structure of telomerase with Telomeric DNA. Cell. 2018;173:1179-1190.

Hockemeyer D, Collins K. Control of telomerase action at human telomeres. Nat Struct Mol Biol. 2015;22:848-852.

Dejene EA, Li Y, Showkatian Z, Ling H, Seto E. Regulation of poly(a)-specific ribonuclease activity by reversible lysine acetylation. J Biol Chem. 2020;295:10255-10270.

Ghanim GE, Fountain AJ, van Roon AM, et al. Structure of human telomerase holoenzyme with bound telomeric DNA. Nature. 2021;593:449-453.

Schmidt JC, Zaug AJ, Kufer R, Cech TR. Dynamics of human telomerase recruitment depend on template- telomere base pairing. Mol Biol Cell. 2018;29:869-880.

Schaich MA, Sanford SL, Welfer GA, et al. Mechanisms of nucleotide selection by telomerase. Elife. 2020;9:e55438.

Greider CW. Regulating telomere length from the inside out: the replication fork model. Genes Dev. 2016;30:1483-1491.

Rowland TJ, Dumbović G, Hass EP, Rinn JL, Cech TR. Single-cell imaging reveals unexpected heterogeneity of telomerase reverse transcriptase expression across human cancer cell lines. Proc Natl Acad Sci U S A. 2019;116:18488-18497.

Chiba K, Vogan JM, Wu RA, et al. Endogenous telomerase reverse transcriptase N-terminal tagging affects human telomerase function at telomeres in vivo. Mol Cell Biol. 2017;37:e00541-16.

Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet. 2012;13:693-704.

Sayed ME, Cheng A, Yadav GP, et al. Catalysis-dependent inactivation of human telomerase and its reactivation by intracellular telomerase-activating factors (iTAFs). J Biol Chem. 2019;294:11579-11596.

Pike AM, Strong MA, Ouyang JPT, Greider CW. TIN2 functions with TPP1/POT1 to stimulate telomerase processivity. Mol Cell Biol. 2019;39:e00593-18.

Chen LY, Redon S, Lingner J. The human CST complex is a terminator of telomerase activity. Nature. 2012;488:540-544.

Lim CJ, Barbour AT, Zaug AJ, et al. The structure of human CST reveals a decameric assembly bound to telomeric DNA. Science. 2020;368:1081-1085.

Boyle JM, Hennick KM, Regalado SG, et al. Telomere length set point regulation in human pluripotent stem cells critically depends on the shelterin protein TPP1. Mol Biol Cell. 2020;31:2583-2596.

Cheng D, Zhao Y, Wang S, et al. Repression of telomerase gene promoter requires human-specific genomic context and is mediated by multiple HDAC1-containing corepressor complexes. FASEB J. 2017;31:1165-1178.

Penev A, Bazley A, Shen M, Boeke JD, Savage SA, Sfeir A. Alternative splicing is a developmental switch for hTERT expression. Mol Cell. 2021;81:2349-2360.

McNally EJ, Luncsford PJ, Armanios M. Long telomeres and cancer risk: the price of cellular immortality. J Clin Invest. 2019;129:3474-3481.

Nassour J, Schmidt TT, Karlseder J. Telomeres and cancer: resolving the paradox. Annu Rev Cancer Biol. 2021;5:59-77.

Roake CM, Artandi SE. Control of cellular aging, tissue function, and cancer by p53 downstream of telomeres. Cold Spring Harb Perspect Med. 2017;7:a026088.

de Lange T. How telomeres solve the end-protection problem. Science. 2009;326:948-952.

Cleal K, Baird DM. Catastrophic endgames: emerging mechanisms of telomere-driven genomic instability. Trends Genet. 2020;36:347-359.

Pan-cancer analysis of whole genomes. Nature. 2020;578:82-93.

Sieverling L, Hong C, Koser SD, et al. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2020;11:733.

Barthel FP, Wei W, Tang M, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017;49:349-357.

Péneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut. 2021. https://doi.org/10.1136/gutjnl-2020-323153

Hennessey RC, Brown KM. Cancer regulatory variation. Curr Opin Genet Dev. 2021;66:41-49.

Peifer M, Hertwig F, Roels F, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700-704.

Valentijn LJ, Koster J, Zwijnenburg DA, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015;47:1411-1414.

Rowland TJ, Bonham AJ, Cech TR. Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers. Mol Oncol. 2020;14:2358-2374.

Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959-961.

Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957-959.

Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet. 2019;20:299-309.

Chiba K, Lorbeer FK, Shain AH, et al. Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science. 2017;357:1416-1420.

Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife. 2015;4:e07918.

Heidenreich B, Kumar R. Altered TERT promoter and other genomic regulatory elements: occurrence and impact. Int J Cancer. 2017;141:867-876.

Lorbeer FK, Hockemeyer D. TERT promoter mutations and telomeres during tumorigenesis. Curr Opin Genet Dev. 2020;60:56-62.

Rheinbay E, Nielsen MM, Abascal F, et al. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020;578:102-111.

Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505:302-308.

Harland M, Petljak M, Robles-Espinoza CD, et al. Germline TERT promoter mutations are rare in familial melanoma. Fam Cancer. 2016;15:139-144.

Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014;46:482-486.

Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet. 2014;46:478-481.

Aoude LG, Pritchard AL, Robles-Espinoza CD, et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst. 2014;107(2):dju408.

Schmutz I, Mensenkamp AR, Takai KK, et al. TINF2 is a haploinsufficient tumor suppressor that limits telomere length. Elife. 2020;9:e61235.

Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110:6021-6026.

Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.

Bell RJ, Rube HT, Xavier-Magalhaes A, et al. Understanding TERT promoter mutations: a common path to immortality. Mol Cancer Res. 2016;14:315-323.

Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014;24:30-37.

Maturo MG, Rachakonda S, Heidenreich B, et al. Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma. Sci Rep. 2020;10:8005.

Heidenreich B, Nagore E, Rachakonda PS, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun. 2014;5:3401.

Griewank KG, Murali R, Schilling B, et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One. 2013;8:e80354.

Scott GA, Laughlin TS, Rothberg PG. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol. 2014;27:516-523.

Denisova E, Heidenreich B, Nagore E, et al. Frequent DPH3 promoter mutations in skin cancers. Oncotarget. 2015;6:35922-35930.

Srinivas N, Neittaanmäki N, Heidenreich B, et al. TERT promoter mutations in actinic keratosis before and after treatment. Int J Cancer. 2020;146:2932-2934.

Yu D, Horton JR, Yang J, et al. Human MettL3-MettL14 RNA adenine methyltransferase complex is active on double-stranded DNA containing lesions. Nucleic Acids Res. 2021;gkab460.

Nagore E, Heidenreich B, Rachakonda S, et al. TERT promoter mutations in melanoma survival. Int J Cancer. 2016;139:75-84.

Andrés-Lencina JJ, Rachakonda S, García-Casado Z, et al. TERT promoter mutation subtypes and survival in stage I and II melanoma patients. Int J Cancer. 2019;144:1027-1036.

Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013;110:17426-17431.

Campanella NC, Celestino R, Pestana A, et al. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Eur J Hum Genet. 2015;23:877-879.

Wu RC, Ayhan A, Maeda D, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol. 2014;232:473-481.

Wu S, Huang P, Li C, et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur Urol. 2014;65:274-277.

Stoehr R, Taubert H, Zinnall U, et al. Frequency of TERT promoter mutations in prostate cancer. Pathobiology. 2015;82:53-57.

Panero J, Alves-Paiva RM, Roisman A, et al. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma. Am J Hematol. 2016;91:481-485.

Huang DS, Wang Z, He XJ, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer. 2015;51:969-976.

Revy P, Kannengiesser C, Fischer A. Somatic genetic rescue in Mendelian haematopoietic diseases. Nat Rev Genet. 2019;20:582-598.

Gutierrez-Rodrigues F, Donaires FS, Pinto A, et al. Pathogenic TERT promoter variants in telomere diseases. Genet Med. 2019;21:1594-1602.

Maryoung L, Yue Y, Young A, et al. Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations. J Clin Invest. 2017;127:982-986.

Stern JL, Hibshman G, Hu K, et al. Mesenchymal and MAPK expression signatures associate with telomerase promoter mutations in multiple cancers. Mol Cancer Res. 2020;18:1050-1062.

Noureen N, Wu S, Lv Y, et al. Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation. Nat Commun. 2021;12:139.

Li Y, Cheng HS, Chng WJ, Tergaonkar V. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proc Natl Acad Sci U S A. 2016;113:14402-14407.

Pinyol R, Tovar V, Llovet JM. TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma. J Hepatol. 2014;61:685-687.

Pilati C, Letouzé E, Nault JC, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25:428-441.

Körber V, Yang J, Barah P, et al. Evolutionary trajectories of IDH(WT) glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell. 2019;35:692-704.

Griewank KG, Murali R, Puig-Butille JA, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst. 2014;106(9):dju246.

Nagore E, Heidenreich B, Requena C, et al. TERT promoter mutations associate with fast-growing melanoma. Pigment Cell Melanoma Res. 2016;29:236-238.

Nagore E, Rachakonda S, Kumar R. TERT promoter mutations in melanoma survival. Oncotarget. 2019;10:1546-1548.

Gandini S, Zanna I, De Angelis S, et al. TERT promoter mutations and melanoma survival: a comprehensive literature review and meta-analysis. Crit Rev Oncol Hematol. 2021;160:103288.

Walton KE, Garfield EM, Zhang B, et al. The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: a retrospective, case-control study. J Am Acad Dermatol. 2019;80:685-693.

Thomas NE, Edmiston SN, Tsai YS, et al. Utility of TERT promoter mutations for cutaneous primary melanoma diagnosis. Am J Dermatopathol. 2019;41:264-272.

Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373:1926-1936.

Tang J, Fewings E, Chang D, et al. The genomic landscapes of individual melanocytes from human skin. Nature. 2020;586:600-605.

Warrick JI, Knowles MA, Yves A, et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. II. Molecular pathology of bladder Cancer: Progress and challenges. Am J Surg Pathol. 2020;44:e30-e46.

Kessler T, Berberich A, Sadik A, et al. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Med. 2020;9:8373-8385.

Heidenreich B, Rachakonda PS, Hosen I, et al. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget. 2015;6:10617-10633.

Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372:2499-2508.

Labussière M, Boisselier B, Mokhtari K, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014;83:1200-1206.

Powter B, Jeffreys SA, Sareen H, et al. Human TERT promoter mutations as a prognostic biomarker in glioma. J Cancer Res Clin Oncol. 2021;147:1007-1017.

Ersoy TF, Keil VC, Hadizadeh DR, et al. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma. Neuroradiology. 2017;59:1223-1231.

Simon M, Hosen I, Gousias K, et al. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015;17:45-52.

Li X, Qian X, Wang B, et al. Programmable base editing of mutated TERT promoter inhibits brain tumour growth. Nat Cell Biol. 2020;22:282-288.

Spiegl-Kreinecker S, Lötsch D, Neumayer K, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol. 2018;20:1584-1593.

Pirker C, Bilecz A, Grusch M, et al. Telomerase reverse transcriptase promoter mutations identify a Genomically defined and highly aggressive human pleural mesothelioma subgroup. Clin Cancer Res. 2020;26:3819-3830.

Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32:2718-2726.

Park J, Lee S, Kim K, et al. TERT promoter mutations and the 8th edition TNM classification in predicting the survival of thyroid cancer patients. Cancer. 2021;13:648.

Manrique-Silva E, Rachakonda S, Millan-Esteban D, et al. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients. Br J Dermatol. 2021;184:504-513.

Ningarhari M, Caruso S, Hirsch TZ, et al. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. J Hepatol. 2021;74:1155-1166.

Vallarelli AF, Rachakonda PS, André J, et al. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget. 2016;7:53127-53136.

Gabler L, Lötsch D, Kirchhofer D, et al. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma. Acta Neuropathol Commun. 2019;7:128.

Wu Y, Shi L, Zhao Y, et al. Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers. npj Precis Oncol. 2021;5:3.

Liu R, Zhang T, Zhu G, Xing M. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun. 2018;9:579.

Liu R, Tan J, Shen X, et al. Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2. Proc Natl Acad Sci U S A. 2021;118:e2022779118.

Tan J, Liu R, Zhu G, Umbricht CB, Xing M. TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles heel. Proc Natl Acad Sci U S A. 2020;117:15846-15851.

Hosen I, Rachakonda PS, Heidenreich B, et al. TERT promoter mutations in clear cell renal cell carcinoma. Int J Cancer. 2015;136:2448-2452.

Hosen I, Rachakonda PS, Heidenreich B, et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J Cancer. 2015;137:1621-1629.

Xu D, Dwyer J, Li H, Duan W, Liu JP. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem. 2008;283:23567-23580.

Zhang F, Wang S, Zhu J. ETS variant transcription factor 5 and c-Myc cooperate in derepressing the human telomerase gene promoter via composite ETS/E-box motifs. J Biol Chem. 2020;295:10062-10075.

Kanaya T, Kyo S, Hamada K, et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res. 2000;6:1239-1247.

Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008;99:1528-1538.

Lee S, Opresko P, Pappo A, Kirkwood JM, Bahrami A. Association of TERT promoter mutations with telomerase expression in melanoma. Pigment Cell Melanoma Res. 2016;29:391-393.

Arita H, Narita Y, Takami H, et al. TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol. 2013;126:939-941.

Bahrami A, Lee S, Schaefer IM, et al. TERT promoter mutations and prognosis in solitary fibrous tumor. Mod Pathol. 2016;29:1511-1522.

Lötsch D, Ghanim B, Laaber M, et al. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol. 2013;15:423-432.

Borah S, Xi L, Zaug AJ, et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 2015;347:1006-1010.

Genomic classification of cutaneous melanoma. Cell. 2015;161:1681-1696.

Corces MR, Granja JM, Shams S, et al. The chromatin accessibility landscape of primary human cancers. Science. 2018;362:eaav1898.

Cooper CD, Newman JA, Aitkenhead H, Allerston CK, Gileadi O. Structures of the Ets protein DNA-binding domains of transcription factors Etv1, Etv4, Etv5, and Fev: determinants of DNA binding and redox regulation by disulfide bond formation. J Biol Chem. 2015;290:13692-13709.

Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC. The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer. 2017;17:337-351.

Bell RJ, Rube HT, Kreig A, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015;348:1036-1039.

Stern JL, Theodorescu D, Vogelstein B, Papadopoulos N, Cech TR. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev. 2015;29:2219-2224.

Akıncılar SC, Khattar E, Boon PL, Unal B, Fullwood MJ, Tergaonkar V. Long-range chromatin interactions drive mutant TERT promoter activation. Cancer Discov. 2016;6:1276-1291.

Huang FW, Bielski CM, Rinne ML, et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015;4:e176.

Mancini A, Xavier-Magalhães A, Woods WS, et al. Disruption of the β1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner. Cancer Cell. 2018;34:513-528.

Amen AM, Fellmann C, Soczek KM, et al. Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. Proc Natl Acad Sci U S A. 2021;118:e2008772118.

Bullock M, Lim G, Zhu Y, Åberg H, Kurdyukov S, Clifton-Bligh R. ETS factor ETV5 activates the mutant telomerase reverse transcriptase promoter in thyroid cancer. Thyroid. 2019;29:1623-1633.

Li Y, Zhou QL, Sun W, et al. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol. 2015;17:1327-1338.

Xu X, Li Y, Bharath SR, et al. Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1. Nat Commun. 2018;9:3183.

Monsen RC, DeLeeuw L, Dean WL, et al. The hTERT core promoter forms three parallel G-quadruplexes. Nucleic Acids Res. 2020;48:5720-5734.

Kang HJ, Cui Y, Yin H, et al. A pharmacological chaperone molecule induces cancer cell death by restoring tertiary DNA structures in mutant hTERT promoters. J Am Chem Soc. 2016;138:13673-13692.

Sengupta A, Roy SS, Chowdhury S. Non-duplex G-quadruplex DNA structure: a developing story from predicted sequences to DNA structure-dependent epigenetics and beyond. Acc Chem Res. 2021;54:46-56.

Sharma S, Mukherjee AK, Roy SS, et al. Human telomerase is directly regulated by non-telomeric TRF2-G-quadruplex interaction. Cell Rep. 2021;35:109154.

Demanelis K, Jasmine F, Chen LS, et al. Determinants of telomere length across human tissues. Science. 2020;369:eaaz6876.

Rachakonda S, Kong H, Srinivas N, et al. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk. Genes Chromosomes Cancer. 2018;57:564-572.

Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6:611-622.

Zhang Y, Shen J, Ming W, Lee YP, Santella RM. Telomere length in hepatocellular carcinoma and paired adjacent non-tumor tissues by quantitative PCR. Cancer Invest. 2007;25:668-677.

Meeker AK, Hicks JL, Iacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res. 2004;10:3317-3326.

Hirashima K, Migita T, Sato S, Muramatsu Y, Ishikawa Y, Seimiya H. Telomere length influences cancer cell differentiation in vivo. Mol Cell Biol. 2013;33:2988-2995.

Liu T, Wang N, Cao J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014;33:4978-4984.

Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164:550-563.

Mitchell TJ, Turajlic S, Rowan A, et al. Timing the landmark events in the evolution of clear cell renal cell Cancer: TRACERx renal. Cell. 2018;173:611-623.

Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175-180.

Mason PJ, Perdigones N. Telomere biology and translational research. Transl Res. 2013;162:333-342.

Campbell PJ. Telomeres and cancer: from crisis to stability to crisis to stability. Cell. 2012;148:633-635.

Bhargava R, Fischer M, O'Sullivan RJ. Genome rearrangements associated with aberrant telomere maintenance. Curr Opin Genet Dev. 2020;60:31-40.

Vessoni AT, Zhang T, Quinet A, et al. Telomere erosion in human pluripotent stem cells leads to ATR-mediated mitotic catastrophe. J Cell Biol. 2021;220:e202011014.

Zeng H, Jorapur A, Shain AH, et al. Bi-allelic loss of CDKN2A initiates melanoma invasion via BRN2 activation. Cancer Cell. 2018;34:56-68.

Haycock PC, Burgess S, Nounu A, et al. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol. 2017;3:636-651.

Aviv A, Anderson JJ, Shay JW. Mutations, cancer and the telomere length paradox. Trends Cancer. 2017;3:253-258.

Lahouel K, Younes L, Danilova L, et al. Revisiting the tumorigenesis timeline with a data-driven generative model. Proc Natl Acad Sci USA. 2020;117:857-864.

Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. 2017;355:1330-1334.

Codd V, Wang Q, Allara E, et al. Polygenic basis and biomedical consequences of telomere length variation. medRxiv. 2021. https://doi.org/10.1101/2021.03.23.21253516

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-1558.

Chen F, Zhang Y, Creighton CJ. Systematic identification of non-coding somatic single nucleotide variants associated with altered transcription and DNA methylation in adult and pediatric cancers. NAR Cancer. 2021;3:zcab001.

Moore JE, Purcaro MJ, Pratt HE, et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature. 2020;583:699-710.

Snyder MP, Gingeras TR, Moore JE, et al. Perspectives on ENCODE. Nature. 2020;583:693-698.

Sur I, Taipale J. The role of enhancers in cancer. Nat Rev Cancer. 2016;16:483-493.

Rheinbay E, Parasuraman P, Grimsby J, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547:55-60.

Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet. 2014;46:1160-1165.

Fredriksson NJ, Ny L, Nilsson JA, Larsson E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet. 2014;46:1258-1263.

Mansour MR, Abraham BJ, Anders L, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014;346:1373-1377.

Giunta S. Decoding human cancer with whole genome sequencing: a review of PCAWG project studies published in February 2020. Cancer Metastasis Rev. 2021;1-16.

Renaud S, Loukinov D, Abdullaev Z, et al. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 2007;35:1245-1256.

Makowski MM, Willems E, Fang J, et al. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations. Proteomics. 2016;16:417-426.

Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 1653;2003:25-40.

Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev. 2007;17:31-39.

Dhomen N, Reis-Filho JS, da Rocha DS, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15:294-303.

Desideri E, Cavallo AL, Baccarini M. Alike but different: RAF paralogs and their signaling outputs. Cell. 2015;161:967-970.

Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.

Wellbrock C, Karasarides M, Marais R. The RAF proteins take Centre stage. Nat Rev Mol Cell Biol. 2004;5:875-885.

Rands CM, Meader S, Ponting CP, Lunter G. 8.2% of the human genome is constrained: variation in rates of turnover across functional element classes in the human lineage. PLoS Genet. 2014;10:e1004525.

Doolittle WF. Is junk DNA bunk? A critique of ENCODE. Proc Natl Acad Sci U S A. 2013;110:5294-5300.

Doolittle WF, Brunet TDP. On causal roles and selected effects: our genome is mostly junk. BMC Biol. 2017;15:116.

Graur D. An upper limit on the functional fraction of the human genome. Genome Biol Evol. 2017;9:1880-1885.

Galeota-Sprung B, Sniegowski P, Ewens W. Mutational load and the functional fraction of the human genome. Genome Biol Evol. 2020;12:273-281.

Huang S. Reconciling non-genetic plasticity with somatic evolution in cancer. Trends Cancer. 2021;7:309-322.

Vedelek B, Maddali AK, Davenova N, Vedelek V, Boros IM. TERT promoter alterations could provide a solution for Peto's paradox in rodents. Sci Rep. 2020;10:20815.

CTNNB1 mutations, TERT polymorphism and CD8+ cell densities in resected hepatocellular carcinoma are associated with longer time to recurrence

Mutational Characterization of Cutaneous Melanoma Supports Divergent Pathways Model for Melanoma Development